Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

March 2023

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 MARCH 2023

- Calcium carbonate (Calcium Carbonate PAI) oral liq 250 mg per ml (100 mg elemental per ml), 473 ml – new listing
- Ceftriaxone (Ceftriaxone-AFT) inj 2 g vial, 5 inj pack size – new listing and addition of PSS
- Ceftriaxone (Ceftriaxone-AFT) inj 2 g vial, 1 inj pack size – to be delisted 1 July 2023
- Ciprofloxacin (Cipflox) inj 2 mg per ml, 100 ml bag – to be delisted 1 May 2023
- Clindamycin (Hameln) inj 150 mg per ml, 4 ml ampoule – new listing and addition of PSS
- Clindamycin (Dalacin C) inj 150 mg per ml, 4 ml ampoule – to be delisted 1 August 2023
- Clozapine (Clozaril) tab 25 mg and 100 mg – new Pharmacode listings
- Compound electrolytes with glucose [dextrose] (Pedialyte – Bubblegum) soln with electrolytes (2 x 500 ml), 1,000 ml – price increase
- Darunavir (Darunavir Mylan) tab 600 mg – to be delisted 1 August 2023
- Dipyridamole (Pytazen SR) tab long-acting 150 mg – price increase
- Ethinyloestradiol with levonorgestrel (Lo-Oralcon 20 ED) tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – new listing and addition of PSS
- Ethinyloestradiol with levonorgestrel (Migrogynon 20 ED) tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – to be delisted 1 August 2023
- Ethinyloestradiol with levonorgestrel (Oralcon 30 ED) tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – new listing and addition of PSS
- Ethinyloestradiol with levonorgestrel (Levlen ED) tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – to be delisted 1 August 2023
- Flecainide acetate (Flecainide Controlled Release Teva) cap long-acting 100 mg and 200 mg – price decrease and addition of PSS
- Flecainide acetate (Tambocor) inj 10 mg per ml, 15 ml ampoule – price increase
- Folic acid (Folic Acid Viatris) tab 5 mg – new listing and addition of HSS
- Gadodiamide (Omniscan) inj 287 mg per ml, 10 ml prefilled syringe, 10 ml vial, 5 ml vial and 15 ml prefilled syringe – delisted 1 March 2023
- Glycerol (Lax-suppositories Glycerol) suppos 2.8/4.0 g – presentation description change
- Glyceryl trinitrate (Nitrolingual Pump Spray) oral pump spray, 400 mcg per dose – price increase
- Hydrocortisone (Noumed) crm 1%, 500 g – new listing and addition of PSS

Summary of decisions – effective 1 March 2023 (continued)

- Hydrocortisone (PSM) crm 1%, 500 g to be delisted 1 August 2023
- Hydrocortisone acetate (Colifoam) rectal foam 10%, CFC free (14 applications), 15 g – new pack size
- Hydrogen peroxide (Crystaderm) crm 1%, 10 g – new listing
- Hydrogen peroxide (Crystaderm) crm 1%, 15 g – to be delisted 1 June 2023
- Influenza vaccine (Afluria Quad Junior (2023 Formulation)) inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) – new listing
- Influenza vaccine (Afluria Quad (2023 Formulation)) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – new listing
- Influenza vaccine (Afluria Quad and Afluria Quad Junior (2022 Formulations)) inj – delisted 1 March 2023
- Iohexol (Omnipaque) inj 350 mg per ml (iodine equivalent), 20 ml bottle – delisted 1 March 2023
- Liraglutide (Victoza) inj 6 mg per ml, 3 ml prefilled pen – new listing
- Mask for spacer device (e-chamber Mask) small – price increase
- Meningococcal B multicomponent vaccine (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe – amended restriction criteria
- Metformin hydrochloride (Metformin Viatris) tab immediate-release 500 mg – PSS added
- Metformin hydrochloride (Metformin Mylan) tab immediate-release 500 mg – to be delisted 1 August 2023 and removal of PSS
- Metoprolol tartrate (Metoprolol IV Viatris) inj 1 mg per ml, 5 ml vial – new listing
- Midodrine (Midodrine Medsurge) tab 2.5 mg and 5 mg – new listing and addition of PSS
- Ondansetron (Periset) tab 4 mg and 8 mg – new listing and addition of PSS
- Ondansetron (Onrex) tab 4 mg and 8 mg – to be delisted 1 August 2023
- Pethidine hydrochloride (Noumed Pethidine) tab 50 mg – new listing and addition of PSS
- Pethidine hydrochloride (PSM) tab 50 mg – to be delisted 1 August 2023
- Pholcodine (AFT Pholcodine Linctus BP) oral liq 1 mg per ml, 200 ml – to be delisted 1 August 2023
- Pravastatin (Pravastatin Viatris) tab 20 mg – new listing
- Pyridostigmine bromide (Mestinon) tab 60 mg – price increase
- Rotavirus oral vaccine (Rotarix) oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube – new listing

Summary of decisions – effective 1 March 2023 (continued)

- Roxithromycin (Arrow-Roxithromycin) tab 150 mg and 300 mg – price decrease and addition of PSS
- Simvastatin (Simvastatin Viatris) tab 40 mg – new listing
- Sodium alginate with sodium bicarbonate and calcium carbonate (e.g. Gaviscon Extra Strength) tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg – amended example brand name
- Space device 220 ml (single patient) (e-chamber Turbo) and 510 ml (single patient) (e-chamber La Grande) – price increase
- Tetracycline (Accord) tab 250 mg – price increase
- Theophylline tab long-acting 250 mg (Nuelin-SR) and oral liq 80 mg per 15 ml (Nuelin) – price increase
- Timolol (Timoptol XE) eye drops 0.5%, gel forming, 2.5 ml – to be delisted 1 March 2024
- Vinorelbine (Navelbine) inj 10 mg per ml, 1 ml and 5 ml vial – to be delisted 1 October 2024
- Voriconazole (AFT) inj 200 mg vial – new listing and addition of PSS
- Voriconazole (Neo Health) inj 200 mg vial – to be delisted 1 August 2023
- Zoledronic acid (Zoledronic acid Mylan and Zoledronic acid Viatris) inj 4 mg per 5 ml, vial – restriction criteria removed
- Zoledronic acid inj 5 mg per 100 ml, bag (Zoledronic Acid Viatris) and inj 5 mg per 100 ml, vial (Aclasta) – restriction criteria removed

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 March 2023

ALIMENTARY TRACT AND METABOLISM

5 CALCIUM CARBONATE (new listing)
➔ Oral liq 250 mg per ml (100 mg elemental per ml) ..... 47.30 473 ml Calcium Carbonate PAI

5 SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE (amended example brand)
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg *e.g. Gaviscon ~~Double~~ **Extra** Strength*

6 HYDROCORTISONE ACETATE (new pack size)
Rectal foam 10%, CFC free (14 applications) ..... 26.55 15 g Colifoam

11 LIRAGLUTIDE (new listing)
Note: Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.
➔ Inj 6 mg per ml, 3 ml prefilled pen ..... 383.72 3 Victoza

Restricted
Initiation
Any of the following:
1. For continuation use; or
2. Patient has previously received an initial Special Authority approval for either an SGLT-2 inhibitor or GLP-1 agonist; or
3. All of the following:
   - 3.1 Patient has type 2 diabetes; and
   - 3.2 Any of the following:
     - 3.2.1 Patient is Māori or any Pacific ethnicity*; or
     - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
     - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
     - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
     - 3.2.5 Patient has diabetic kidney disease (see note b)*; and
   - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent eg metformin, vildagliptin, or insulin) for at least 3 months.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (ie angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m^2 in the presence of diabetes, without alternative cause

11 METFORMIN HYDROCHLORIDE (PSS added)
Tab immediate-release 500 mg – **1% DV Mar-23 to 2024** ..... 14.74 1,000 **Metformin Viatris**

11 METFORMIN HYDROCHLORIDE (delisting and removal of PSS)
Tab immediate-release 500 mg
– 1% DV Mar-22 to ~~2024~~ **28/2/23** ..... 14.74 1,000 **Metformin Mylan**
Note – Metformin Mylan tab immediate-release 500 mg to be delisted from 1 August 2023.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 March 2023 (continued)				
15	GLYCEROL (presentation description change) Suppos **2.8/4.0 g ~~4 g~~ – 5% DV Feb-23 to 2025**	10.39	20	**Lax-suppositories Glycerol**
	Note: DV limit applies to glycerol suppository presentations.			
BLOOD AND BLOOD FORMING ORGANS				
29	FOLIC ACID (new listing and addition of HSS) Tab 5 mg – **1% DV Mar-23 to 2024**	5.82	100	**Folic Acid Viatris**
36	DIPYRIDAMOLE (↑ price) Tab long-acting 150 mg	13.93	60	Pytazen SR
41	COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] (↑ price) Soln with electrolytes (2 × 500 ml)	8.55	1,000 ml	Pedialyte - Bubblegum
CARDIOVASCULAR SYSTEM				
45	FLECAINIDE ACETATE (↓ price and addition of PSS) Cap long-acting 100 mg – **5% DV Aug-23 to 2025**	35.78	90	**Flecainide Controlled Release Teva**
	Cap long-acting 200 mg – **5% DV Aug-23 to 2025**	54.28	90	**Flecainide Controlled Release Teva**
45	FLECAINIDE ACETATE (↑ price) Inj 10 mg per ml, 15 ml ampoule	104.00	5	Tambocor
46	MIDODRINE (new listing and addition of PSS) ➔ Tab 2.5 mg – **5% DV Aug-23 to 2025** ➔ Tab 5 mg – **5% DV Aug-23 to 2025**	38.23 59.98	100 100	**Midodrine Medsurge** **Midodrine Medsurge**
47	METOPROLOL TARTRATE (new listing) Inj 1 mg per ml, 5 ml vial	26.50	5	Metoprolol IV Viatris
51	PRAVASTATIN (new listing) Tab 20 mg	2.11	28	Pravastatin Viatris
51	SIMVASTATIN (new listing Tab 40 mg	3.58	90	Simvastatin Viatris
52	GLYCERYL TRINITRATE (↑ price) Oral pump spray, 400 mcg per dose	7.48	250 dose	Nitrolingual Pump Spray

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 March 2023 (continued)

DERMATOLOGICALS

58 HYDROGEN PEROXIDE (pack size change)
Crm 1% ..... 8.56 10 g Crystaderm
Note – Crystaderm crm 1% 15 g to be delisted from 1 June 2023.

61 HYDROCORTISONE (new listing and addition of PSS)
Crm 1%, 500 g – **5% DV Aug-23 to 2025** ..... 20.40 500 g **Noumed**
Note – Hydrocortisone (PSM) crm 1%, 500 g to be delisted from 1 August 2023.

GENITO-URINARY SYSTEM

65 ETHINYLOESTRADIOL WITH LEVONORGESTREL (new listing and addition of PSS)
Tab 20 mcg with levonorgestrel 100 mcg
and 7 inert tablets – **5% DV Aug-23 to 2025** ..... 1.50 84 **Lo-Oralcon 20 ED**
Note – Microgynon 20 ED tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets to be delisted from 1 August 2023.

65 ETHINYLOESTRADIOL WITH LEVONORGESTREL (new listing and addition of PSS)
Tab 30 mcg with levonorgestrel 150 mcg
and 7 inert tablets – **5% DV Aug-23 to 2025** ..... 1.50 84 **Oralcon 30 ED**
Note – Levlen ED tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets to be delisted from 1 August 2023.

HORMONE PREPARATIONS

69 ZOLEDRONIC ACID (restriction criteria removed)
➔ Inj 4 mg per 5 ml, vial – **5% DV Dec-21 to 2024** ..... 18.00 1 **Zoledronic acid Mylan**
Zoledronic acid Viatris

~~Restricted~~
~~Initiation – bone metastases~~
~~Any of the following:~~
~~1 Patient has hypercalcaemia of malignancy; or~~
~~2 Both:~~
~~2.1 Patient has bone metastases or involvement; and~~
~~2.2 Patient has severe bone pain resistant to standard first-line treatments; or~~
~~3 Both:~~
~~3.1 Patient has bone metastases or involvement; and~~
~~3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).~~

~~Initiation – early breast cancer*~~
~~All of the following:~~
~~1 Treatment to be used as adjuvant therapy for early breast cancer; and~~
~~2 Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and~~
~~3 Treatment to be administered at a minimum interval of 6-monthly for a maximum of 3 years.~~
~~Note: Indications marked with * are unapproved indications.~~

~~Initiation – symptomatic hypercalcaemia*~~
~~Any relevant practitioner~~
~~Patient has symptomatic hypercalcaemia.~~
~~Note: Indications marked with * are unapproved indications~~.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 March 2023 (continued)

INFECTIONS

80 CEFTRIAXONE (new pack size listing and addition of PSS)
Inj 2 g vial – **5% DV Aug-23 to 2025** 7.85 5 **Ceftriaxone-AFT**
Note – Ceftriaxone-AFT inj 2 g vial, 1 inj pack to be delisted from 1 July 2023.

82 ROXITHROMYCIN (↓ price and addition of PSS)
Tab 150 mg – **5% DV Aug-23 to 2025** 13.19 50 **Arrow-Roxithromycin**
Tab 300 mg – **5% DV Aug-23 to 2025** 25.00 50 **Arrow-Roxithromycin**

84 CIPROFLOXACIN (delisting)
➔ Inj 2 mg per ml, 100 ml bag 68.20 10 Cipflox
Note – Cipflox inj 2 mg per ml, 100 ml bag to be delisted from 1 May 2023.

85 CLINDAMYCIN (new listing and addition of PSS)
➔ Inj 150 mg per ml, 4 ml ampoule – **5% DV Aug-23 to 2025** 35.10 10 **Hameln**
Note – Dalacin C inj 150 mg per ml, 4 ml ampoule to be delisted from 1 August 2023.

85 TETRACYCLINE (↑ price)
Tab 250 mg 58.20 28 Accord

88 VORICONAZOLE (new listing and addition of PSS)
➔ Inj 200 mg vial – **5% DV Aug-23 to 2025** 19.85 1 **AFT**
Note – Neo Health inj 200 mg vial to be delisted from 1 August 2023.

96 DARUNAVIR (delisting)
➔ Tab 600 mg 196.65 60 Darunavir Mylan
Note – Darunavir Mylan tab 600 mg to be delisted from 1 August 2023.

MUSCULOSKELETAL SYSTEM

103 PYRIDOSTIGMINE BROMIDE (↑ price)
Tab 60 mg 50.28 100 Mestinon

104 ZOLEDRONIC ACID (restriction criteria removed)
➔ Inj 5 mg per 100 ml, bag – **5% DV Jun-23 to 2025** 22.53 100 ml **Zoledronic Acid Viatris**
➔ Inj 5 mg per 100 ml, vial 60.00 100 ml Aclasta

~~Restricted~~
~~Initiation – Inherited bone fragility disorders~~
~~Any specialist~~
~~Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).~~

~~Initiation – Osteoporosis~~
~~Any specialist~~
~~*Therapy limited to 3 doses*~~
~~Both:~~
~~1. Any of the following:~~
~~1.1. History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or~~
~~1.2. History of one significant osteoporotic fracture demonstrated radiologically, and either the patient~~

continued...

Changes to Section H Part II – effective 1 March 2023 (continued)

continued...

~~is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or~~

~~1.3 History of two significant osteoporotic fractures demonstrated radiologically; or~~

~~1.4 Documented T-Score greater than or equal to -3.0 (see Note); or~~

~~1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or~~

~~1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and~~

~~2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.~~

~~Initiation – glucocorticosteroid therapy~~
~~Any specialist~~
~~*Re-assessment required after 12 months*~~
~~All of the following:~~
~~1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and~~
~~2 Any of the following:~~
~~2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or~~
~~2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or~~
~~2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and~~
~~3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.~~

~~Continuation – glucocorticosteroid therapy~~
~~Any specialist~~
~~*Re-assessment required after 12 months*~~
~~Both:~~
~~1 The patient is continuing systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone equivalents); and~~
~~2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.~~

~~Initiation – Paget's disease~~
~~Any specialist~~
~~*Re-assessment required after 12 months*~~
~~All of the following:~~
~~1 Paget's disease; and~~
~~2 Any of the following:~~
~~2.1 Bone or articular pain; or~~
~~2.2 Bone deformity; or~~
~~2.3 Bone, articular or neurological complications; or~~
~~2.4 Asymptomatic disease, but risk of complications; or~~
~~2.5 Preparation for orthopaedic surgery; and~~
~~3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.~~

~~Continuation – Paget's disease~~
~~Any specialist~~
~~*Re-assessment required after 12 months*~~
~~Both:~~
~~1 Any of the following:~~
~~1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or~~
~~1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or~~

continued...

Changes to Section H Part II – effective 1 March 2023 (continued)

continued...

~~1.3 Symptomatic disease (prescriber determined); and~~

~~2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.~~

~~Initiation – spinal cord injury*~~

~~*Re-assessment required after 12 months*~~

~~All of the following:~~

~~1 Patient has experienced an acute traumatic spinal cord injury in the last six months; and~~

~~2 Patient is being managed by a specialist spinal acute care and rehabilitation unit; and~~

~~3 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.~~

~~Note: Indications marked with * are unapproved indications.~~

~~Continuation – spinal cord injury*~~

~~*Re-assessment required after 6 months*~~

~~Both:~~

~~1 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period; and~~

~~2 The patient has not received more than two doses of zoledronic acid for this indication.~~

~~Note: The patient must not have had more than 1 prior approval. No further renewals will be subsidised. A maximum of 2 vials of zoledronic acid treatment for spinal cord injury will be subsidised. Indications marked with * are unapproved indications.~~

~~Notes:~~

~~a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.~~

~~b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.~~

~~c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.~~

~~d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.~~

NERVOUS SYSTEM

123	PETHIDINE HYDROCHLORIDE (new listing and addition of PSS)			
	Tab 50 mg – **5% DV Aug-23 to 2025**	8.68	10	**Noumed Pethidine**
	Note – PSM tab 50 mg to be delisted from 1 August 2023.			
129	ONDANSETRON (new listing and addition of PSS)			
	Tab 4 mg – **5% DV Aug-23 to 2025**	2.27	50	**Periset**
	Tab 8 mg – **5% DV Aug-23 to 2025**	4.10	50	**Periset**
	Note – Onrex tab 4 mg and 8 mg to be delisted from 1 August 2023.			

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 March 2023 (continued)

130 CLOZAPINE (new listing)

Tab 25 mg	6.69	50	Clozaril
Tab 100 mg	17.33	50	Clozaril

Note – These are the listing of new Pharmacodes 2633353 and 2633361 respectively.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

159 VINORELBINE (delisting)

Inj 10 mg per ml, 1 ml vial	12.00	1	Navelbine
Inj 10 mg per ml, 5 ml vial	56.00	1	Navelbine

Note – Navelbine inj 10 mg per ml, 1 ml and 5 ml vials to be delisted from 1 October 2024

RESPIRATORY SYSTEM AND ALLERGIES

239 PHOLCODINE (delisting)

Oral liq 1 mg per ml	3.09	200 ml	AFT Pholcodine Linctus BP

Note – AFT Pholcodine Linctus BP oral liq 1 mg per ml to be delisted from 1 August 2023.

241 THEOPHYLLINE (↑ price)

Tab long-acting 250 mg	23.94	100	Nuelin-SR
Oral liq 80 mg per 15 ml	17.62	500 ml	Nuelin

SENSORY ORGANS

247 TIMOLOL (delisting)

➔ Eye drops 0.5%, gel forming	3.78	2.5 ml	Timoptol XE

Note – Timoptol XE eye drops 0.5%, gel forming, 2.5 ml brand only to be delisted from 1 March 2024.

VARIOUS

253 IOHEXOL (delisting)

Inj 350 mg per ml (iodine equivalent), 20 ml bottle	82.00	10	Omnipaque

Note – Omnipaque inj 350 mg per ml, 20 ml bottle to be delisted on 1 March 2023.

254 GADODIAMIDE (delisting)

Inj 287 mg per ml, 10 ml prefilled syringe	200.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial	170.00	10	Omniscan
Inj 287 mg per ml, 5 ml vial	120.00	10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe	320.00	10	Omniscan

Note – Omniscan to be delisted on 1 March 2023.

Changes to Section H Part II – effective 1 March 2023 (continued)

VACCINES

280 MENINGOCOCCAL B MULTICOMPONENT VACCINE (amended restriction criteria)

➔ Inj 175 mcg per 0.5 ml prefilled syringe ..... 0.00 | 1 | Bexsero

Restricted

Initiation – Primary immunisation for children up to 12 months of age

Therapy limited to three doses

Either:

1 Three doses for children up to 12 months of age (inclusive) for primary immunisation; or

2 Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025

~~Initiation – Infants under one year of age~~

~~Any of the following:~~

~~1 up to three doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or~~

~~2 up to three doses for close contacts of meningococcal cases of any group; or~~

~~3 up to three doses for child who or has previously had meningococcal disease of any group; or~~

~~4 up to three doses for bone marrow transplant patients; or~~

~~5 up to three doses for person pre- and post-immunosuppression*.~~

Initiation – Person is one year of age or over

Any of the following:

1 up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or

2 up to two doses for close contacts of meningococcal cases of any group; or

3 up to two doses for person who has previously had meningococcal disease of any group; or

4 up to two doses for bone marrow transplant patients; or

5 up to two doses for person pre- and post-immunosuppression* .

Initiation – Person is aged between 13 and 25 years (inclusive)

Therapy limited to two doses

Both

1 Person is aged between 13 and 25 years (inclusive); and

2 Either:

2.1 Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or

2.2 Two doses for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 March 2023 to 28 February 2024.

Note: *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

285 INFLUENZA VACCINE (new listing)

➔ Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) ..... 11.00 | 1 | Afluria Quad Junior (2023 Formulation)

➔ Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) ..... 110.00 | 10 | Afluria Quad (2023 Formulation)

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 March 2023 (continued)

285 INFLUENZA VACCINE (delisted)

➔Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)	11.00	1	Afluria Quad Junior (2022 Formulation)
➔Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	110.00	10	Afluria Quad (2022 Formulation)

Note – Afluria Quad Junior (2022 formulation) inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) and Afluria Quad (2022 formulation) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) delisted 1 March 2023.

287 ROTAVIRUS ORAL VACCINE (new listing)

➔Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube	0.00	10	Rotarix

OPTIONAL PHARMACEUTICALS

290 MASK FOR SPACER DEVICE (↑ price)

Small	2.70	1	e-chamber Mask

290 SPACER DEVICE (↑ price)

220 ml (single patient)	3.65	1	e-chamber Turbo
510 ml (single patient)	5.95	1	e-chamber La Grande

Index
Pharmaceuticals and brands

Index
Pharmaceuticals and brands

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government